^
    Back
    Association details:
    Biomarker:CD36 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    J Natl Cancer Inst
    Title:

    Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab

    Published date:
    07/05/2022
    Excerpt:
    In 180 NeoALTTO patients, high intratumor CD36 expression was independently associated with worse EFS in patients treated with trastuzumab-based therapy (HR: 1.72, 95% CI: 1.20-2.46)...High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy.
    DOI:
    10.1093/jnci/djac126